Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms RSS Feed RSS Feeds


Press Release

Betaseron Drug Analysis 2017: The First Drug to Reach the Market that Modifies the Course of Multiple Sclerosis -

Research and Markets
Posted on: 19 Feb 18

The "Drug Analysis: Betaseron" drug pipelines has been added to's offering.

Betaseron was the first drug to reach the market that modifies the course of multiple sclerosis (MS), after launching in the US in 1994 and the EU in 1996 (where it is marketed as Betaferon). At the time, Betaseron was granted orphan drug status because of its ability to curb MS disease progression as well as reduce the frequency of attacks. However, the US Food and Drug Administration overturned this decision, allowing Avonex (interferon beta-1a; Biogen) to come to market in 1996. In November 2000, Betaseron became the first MS disease modifier to launch in Japan, where it was also granted orphan drug status.

Betaseron is delivered via subcutaneous injection, and was originally developed by Chiron Corporation (a division of Novartis). It is indicated for the treatment of relapsing forms of MS to reduce the frequency of clinical exacerbations, as well as for treating secondary progressive multiple sclerosis (SPMS) in the EU. In 2006, Betaseron's label was extended in both the EU and US to include the treatment of patients with a first clinical event suggestive of MS.

Key Topics Covered:

List of Figures

Figure 1: Betaseron for multiple sclerosis - SWOT analysis

Figure 2: Drug assessment summary for Betaseron in multiple sclerosis

Figure 3: Betaseron sales for multiple sclerosis across the US, Japan, and five major EU markets, by country, 2016-25

List of Tables

Table 1: Betaseron drug profile

Table 2: Betaseron pivotal trial data in multiple sclerosis

Table 3: Betaseron sales for multiple sclerosis across the US, Japan, and five major EU markets, by country ($m), 2016-25

For more information about this drug pipelines report visit

View source version on

Business Wire

Last updated on: 19/02/2018

Site Map | Privacy & Security | Cookies | Terms and Conditions is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.